Genome&Company지놈앤컴퍼니

Genome&Company remains deeply loss-making on trailing results, though its share price is well above its 52-week low and it has joined Eli Lilly's AI drug platform.

Genome&Company (KOSDAQ: 314130) reported trailing twelve-month revenue of ₩24.5B against an operating loss of ₩29.2B and a net loss of ₩41.4B through H1 2026. Its business combines new-target drug discovery licensed to partners, a U.S. contract development and manufacturing unit, and consumer cosmetics and supplements. The share price closed at ₩4,015 on 2026-10-22, with market capitalisation of about ₩210B.

What stands out

• Revenue has been broadly flat to down: ₩24.6B in 2025 after ₩27.7B in 2024, with 2025 revenue down 11.4%, while operating losses stayed near ₩29B.
• Trailing free cash flow was negative at about -₩18.1B, and borrowings of ₩21.4B exceed cash of ₩49.9B on the reported figures.
• Valuation multiples are mixed: price-to-book is 2.9 and price-to-sales 8.6, but there is no meaningful price-to-earnings or EV/EBITDA because earnings are negative.
• Shares are up 48.2% over one year but down 5.1% over one month; foreign ownership fell from 4.2% to 1.9% over the past 60 days.
• Recent news centres on joining Eli Lilly's TuneLab AI drug development platform, which the data does not show as having any financial terms.

What to watch

• The full-year 2026 results and whether losses narrow from the trailing figures shown.
• Ongoing filings on convertible bonds and conversion price adjustments, which could affect share count and dilution; the data does not give the amounts involved.
• Derivatives trading loss and the stock purchase option grant, both filed in August 2026; the data gives no detail on their size.